Aclaris Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	7.83	18.72	31.25	29.5	6.64
Other Revenue	-	-	-	0.26	0.12
Revenue	7.83	18.72	31.25	29.75	6.76
Revenue Growth (YoY)	-58.19%	-40.09%	5.03%	340.05%	4.30%
Cost of Revenue	59.93	49.04	114.25	89.77	48.53
Gross Profit	-52.1	-30.32	-83	-60.02	-41.77
Selling, General & Admin	21.97	22.2	31.51	25.13	23.62
Operating Expenses	21.97	22.2	31.51	25.13	23.62
Operating Income	-74.08	-52.53	-114.51	-85.15	-65.38
Interest & Investment Income	7.64	7.95	8.51	-	-
Other Non Operating Income (Expenses)	3.82	1.91	-	2.95	-1.14
EBT Excluding Unusual Items	-62.62	-42.66	-106	-82.21	-66.53
Merger & Restructuring Charges	-	-	-3.12	-	-
Other Unusual Items	-2.3	-2.5	26.9	-4.7	-24.34
Pretax Income	-64.92	-132.07	-88.85	-86.91	-90.87
Income Tax Expense	-	-	-0.37	-	-
Earnings From Continuing Operations	-64.92	-132.07	-88.48	-86.91	-90.87
Net Income	-64.92	-132.07	-88.48	-86.91	-90.87
Net Income to Common	-64.92	-132.07	-88.48	-86.91	-90.87
Shares Outstanding (Basic)	123	77	70	65	57
Shares Outstanding (Diluted)	123	77	70	65	57
Shares Change (YoY)	58.56%	10.73%	7.05%	14.95%	33.36%
EPS (Basic)	-0.53	-1.71	-1.27	-1.33	-1.60
EPS (Diluted)	-0.53	-1.71	-1.27	-1.33	-1.60
Free Cash Flow	-47.22	-20.2	-79.63	-68.17	-52.44
Free Cash Flow Per Share	-0.39	-0.26	-1.14	-1.04	-0.92
Gross Margin	-	-161.99%	-265.60%	-201.74%	-
Operating Margin	-946.52%	-280.59%	-366.44%	-286.21%	-967.08%
Profit Margin	-829.58%	-705.48%	-283.15%	-292.11%	-1343.96%
Free Cash Flow Margin	-603.42%	-107.89%	-254.84%	-229.13%	-775.65%
EBITDA	-74.04	-52.22	-114.45	-	-65.06
EBITDA Margin	-	-278.95%	-	-	-
D&A For EBITDA	0.04	0.31	0.06	-	0.32
EBIT	-74.08	-52.53	-114.51	-85.15	-65.38
EBIT Margin	-	-280.59%	-	-286.21%	-
Revenue as Reported	7.83	18.72	31.25	29.75	6.76

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q